HAE: Vivasure Acquisition Will Support Earnings Quality Despite Sector Repricing

Haemonetics' updated fair value estimate has edged down by about $1, reflecting analysts' recent trims to price targets across the medical technology group, even as they point to healthy sector fundamentals and mixed revisions following the Vivasure acquisition.

Analyst Commentary

Recent research views on Haemonetics highlight a split between analysts who see upside from the Vivasure acquisition and those who are resetting expectations across the medical technology group after recent sector volatility.

Bullish Takeaways

Bullish analysts link their higher price targets to a constructive view of the Vivasure Medical acquisition, seeing the deal as supportive for Haemonetics' product portfolio and longer term growth ambitions.
The decision to lift a price target to $93 from $90 signals confidence that management can execute on integrating Vivasure and capture the potential value of its polymer implants and delivery systems.
Comments that sector fundamentals remain "healthy" provide context for investors who are focused on whether the broader medical technology backdrop can support Haemonetics' execution and valuation over time.

Bearish Takeaways

Bearish analysts have cut price targets in a range of $6 to $18, which points to more cautious assumptions around Haemonetics' future value, even if ratings on the shares are not uniformly negative.
Some research suggests that after recent Q4 reports across the group, expectations needed to be reset, which can signal concerns about near term execution risk or slower than previously assumed progress.
Where targets have been reduced to levels around $70, investors are being guided to a more conservative stance on what Haemonetics might achieve, particularly when compared with analysts' preferred names in the same sector.
The mix of cuts and modest raises leaves a picture of ongoing debate around the risk and reward balance, with a portion of the Street more focused on integration and valuation risks following the Vivasure deal.

What's in the News

FDA approval expanded the label for Haemonetics' VASCADE MVP XL venous vascular closure system to cover procedures using 10-14F inner diameter and up to 17F outer diameter sheaths, targeting pulsed field ablation and left atrial appendage closure in atrial fibrillation treatment, supported by the AMBULATE EXPAND clinical trial of 77 patients with 0% major and 0% minor access site closure related complications and a median 2.4 hour time to ambulation (Key Developments).
The AMBULATE EXPAND data on VASCADE MVP XL were presented at the AF Symposium 2026 in Boston and published in the Journal of Cardiovascular Electrophysiology, highlighting clinical outcomes in electrophysiology procedures using up to 17F outer diameter sheaths (Key Developments).
Haemonetics received FDA 510(k) clearance for the NexSys PCS Plasma Collection System with Persona PLUS technology, backed by a pivotal trial covering over 30,000 plasma donations from nearly 3,000 donors, with results showing a mid single digit percent higher average plasma volume per donation compared with Persona (Key Developments).
The company issued earnings guidance for the first quarter of 2026, targeting total revenue of US$300 million to US$310 million, with product revenue of US$171 million to US$176 million, and for full year 2026, total revenue of US$1.215 billion to US$1.255 billion with product bookings of US$510 million to US$560 million (Key Developments).
Haemonetics reported that between 28 September 2025 and 27 December 2025 it repurchased 0 shares under its buyback program, while confirming completion of 1,430,579 shares repurchased in total for US$75 million, representing 2.97% of shares under the authorization announced on 8 May 2025 (Key Developments).

Valuation Changes

Fair Value: trimmed slightly to $86.9 from $88.0, a reduction of about 1% in the modelled estimate.
Discount Rate: increased modestly to 8.80% from 8.60%, implying a somewhat higher required return in the cash flow assumptions.
Revenue Growth: adjusted slightly lower to 5.28% from 5.38%, indicating a small recalibration in the long term sales outlook.
Net Profit Margin: nudged higher to 16.10% from 16.05%, reflecting a minor change in expected profitability.
Future P/E: moved marginally lower to 19.0x from 19.1x, signalling a small reset in the earnings multiple applied to the shares.

1 view

Key Takeaways

Accelerated innovation, portfolio transformation, and software adoption are driving share gains, margin expansion, and sustained revenue growth across both plasma and hospital markets.
Demographic shifts and increased demand for blood management position core products for long-term growth, while targeted interventions aim to revitalize underperforming segments.
Heavy dependence on a few U.S.-focused products, intensifying competition, and limited global presence threaten earnings stability, market share, and long-term growth prospects.

Catalysts

About Haemonetics

A medical technology company, provides a suite of hospital technologies solutions in the United States and internationally.What are the underlying business or industry changes driving this perspective?

Rapid innovation and increased adoption of advanced plasma collection systems (NexSys with Persona and Express Plus), as well as new software contracts securing ~80% market share, are driving share gains and supporting double-digit organic growth ex-CSL in the plasma segment; these trends are expected to boost both revenue and net margins as upgrades and center conversions accelerate through FY26 and into FY27.
Rising utilization of TEG-based hemostasis management-fueled by the recent launch of the heparinase neutralization cartridge and ongoing conversion of hospital accounts from lab-based to point-of-care systems-positions the business to capture a greater share of a growing mid-single-digit US and global market, which should propel recurring revenue and support multi-year earnings growth.
Ongoing demographic shifts, such as an aging global population and increased prevalence of chronic diseases requiring more blood management and plasma-derived therapies, point toward a secular upward trend in long-term demand for Haemonetics' core products; this creates a sustained tailwind for revenue growth across hospital and plasma businesses.
Enterprise-wide portfolio transformation-highlighted by the divestiture of low-margin businesses, disciplined capital deployment, and ongoing investment in automation and digital solutions-is driving substantial gross and operating margin expansion (guidance of 26–27% for FY26) and is likely to support further improvements in net margins and free cash flow conversion.
Strategic execution to improve underperforming interventional technologies (notably VASCADE) via new leadership, targeted commercial initiatives, and a focus on higher margin and faster-growing market segments (like vascular closure for electrophysiology procedures) is expected to enable the segment to recover and contribute meaningfully to future revenue growth and margin expansion.

Haemonetics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Haemonetics's revenue will grow by 5.3% annually over the next 3 years.
Analysts assume that profit margins will increase from 13.3% today to 16.1% in 3 years time.
Analysts expect earnings to reach $247.6 million (and earnings per share of $5.2) by about April 2029, up from $175.4 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 19.0x on those 2029 earnings, up from 15.8x today. This future PE is lower than the current PE for the US Medical Equipment industry at 25.7x.
Analysts expect the number of shares outstanding to decline by 3.26% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.8%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Increasing competition in the vascular closure and interventional technology markets, including price-based competitors and legacy players, could pressure Haemonetics' market share, force price concessions, and negatively impact revenue and net margins if executional fixes do not restore growth above market rates.
Heavy reliance on three core products (NexSys, TEG, and VASCADE), each highly concentrated in the U.S. market, exposes Haemonetics to sales volatility and execution risk-especially if ongoing challenges with VASCADE persist or if a product loses relevance or encounters new regulatory hurdles, threatening earnings stability.
Temporary declines in plasma and blood center reported revenues-driven by divestitures and contractual transitions-may conceal underlying cyclicality or structural changes in the plasma collection market; over the long term, cyclicality and improved customer productivity could limit absolute volume growth, impacting revenue and earnings trajectory.
Failure to drive sustained growth and utilization in Interventional Technologies (especially VASCADE) despite management interventions could result in continued underperformance, weaker diversification, and less margin expansion than anticipated, ultimately constraining profitability and earnings growth.
Limited international footprint and dependence on U.S.-driven growth heighten exposure to potential U.S.-centric risks (regulatory, reimbursement, macroeconomic), while slower-than-expected adoption outside the U.S., delayed regulatory approvals, or local competition could cap total addressable market expansion and long-term revenue growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $86.9 for Haemonetics based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $108.0, and the most bearish reporting a price target of just $64.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.5 billion, earnings will come to $247.6 million, and it would be trading on a PE ratio of 19.0x, assuming you use a discount rate of 8.8%.
Given the current share price of $59.56, the analyst price target of $86.9 is 31.5% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Haemonetics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Execution Challenges Will Shift Outlook For Global Plasma And Hemostasis Expansion